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Mills and King (1) recently provided a 27-year follow-up of
the five patients in their 1976 report, which first demon-
strated the feasibility of transcatheter closure of atrial septal
defect (ASD). Over the years, we have tested a number of
devices designed to occlude hemodynamically significant
ASDs (2–6). Although some devices have fallen by the
wayside, one device, the Amplatzer septal occluder (AGA
Medical Corp., Golden Valley, Minnesota), achieved a high
level of clinical efficacy and safety (and U.S. Food and Drug
Administration approval) for ASD closure (7).
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Along the way, it was discovered that the patent foramen
ovale (PFO) might be occluded by similar devices employ-
ing techniques used for ASD occlusion (8). This observa-
tion placed us into the business of PFO closure with its
much murkier indications. Although controversial, many
studies have suggested that patients with PFO, especially
younger patients with atrial septal aneurysm, have a higher
risk of cryptogenic stroke than those with intact atrial
septum (9–11). However, the evidence suggesting that
transcatheter (or surgical) PFO closure to prevent stroke is
more efficacious than medical therapy alone is at present
inconclusive (12,13). Randomized controlled studies com-
paring device PFO closure and medical therapy are under-
way. In the meantime, device closure is being performed if
medical therapy fails to prevent second events.
Particularly in stroke/PFO patients, but also in ASD
patients, the issue of device-related thrombus is important.
Obviously, if a device induces thrombus formation, it may
be contraindicated. If the incidence is low, then the risks of
device-related thrombosis and of subsequent embolic events
need to be carefully evaluated. This is quite obvious, but it
was buried in a pile of other issues when the primary focus
was on ASD closure (7,14).
The original animal pathological studies of the Amplatzer
and other devices showed that deposition of thrombus is
part of a process that eventually leads to endothelization of
devices (15,16). This observation in part led to the routine
use of antiplatelet agents after device implantation. Para-
doxically, routine definitive echocardiographic surveillance
of devices during the most vulnerable period after implant
was not incorporated into most ASD device studies (7,14).
Only after some explanted ASD devices showed thrombus
formation (17,18) and attention shifted to PFO closure for
stroke prevention did routine post-implant transesophageal
echocardiographic (TEE) surveillance come to the fore.
In this issue of the Journal, Krumsdorf et al. (19) report
TEE follow-up of their 10-year 1,000-patient experiences
with device closure of PFO and ASD. Their report focuses
primarily on the important issues of device-related throm-
bosis and its consequences. Despite methodologic imper-
fections, the sheer volume of their experience commands
our attention.
The report emphasizes PFO device closures (59% of the
patients) in adult patients with previous embolic events. It
also includes a substantial experience with ASD occlusion
for hemodynamic indications in patients as young as 13
years. During the course of this study, the investigators
implanted nine different devices, including large numbers of
the following: 418 Amplatzer ASD and PFO devices; 169
CardioSEAL and StarFLEX devices (NMT Medical, Bos-
ton, Massachusetts); 161 Helex devices (W. L. Gore and
Associates, Flagstaff, Arizona); and 127 PFO-Star devices
(Applied Biometrics Inc., Burnsville, Minnesota).
In addition to regular transthoracic echocardiographic
(TTE) follow-ups, the Krumsdorf et al. (19) protocol
included routine TEE studies performed four weeks and six
months after device implantation. The TEE studies were
accomplished, on average, 71% of the scheduled times. If
thrombus was present, additional TEE examinations were
performed as indicated.
According to the researchers, regular follow-up TTE
failed to identify patients with thrombus formation.
Thrombus was identified by TEE evaluation in 15 of the
593 (2.5%) PFO patients and in 5 of the 407 (1.2%) ASD
patients. Thrombus was most often located in the left
atrium and directly contiguous with the device. Of these
patients, 70% (14 of 20) were identified by the four-week
TEE.
Highest on the list of factors associated with thrombus
formation was the type of device. All 326 Amplatzer devices
evaluated at four weeks were free of thrombus. In contrast,
among 119 CardioSEAL and StarFLEX devices observed
at four weeks, 7 (5.9%) had thrombus formation, and
among 76 PFO-Star devices examined at four weeks, 5
(6.6%) had thrombus. The difference between Amplatzer
and these alternative devices was significant (p 0.05). The
Helex device was examined in 122 patients at four weeks
and one thrombus was found.
Other factors associated with thrombus formation were
atrial fibrillation (n  4) and persistent atrial septal aneu-
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rysm (n  4). Factors not associated with thrombus in-
cluded coagulation disorders, coronary disease and risk
factors, patient age, gender, use of protamine during the
implant procedure, type of medical prophylaxis post-
implant, residual shunt post-implant, and device fracture.
In patients with thrombus identified, Krumsdorf et al.
(19) employed medical therapy (most often warfarin) to
dissolve the thrombus. They were successful in 85% of cases
(17 of 20). Three patients required surgery to remove the
thrombus (and device) and to perform surgical closure of
their atrial shunts. Among patients with identified throm-
bus were four (20%) who suffered embolic events consisting
of three minor strokes and one transient ischemic attack.
Krumsdorf et al. (19) offer a number of observations
worthy of careful consideration. These observations impact
on post-implant device surveillance, device selection, and
perhaps also the indications for device implant.
The investigators recommend routine TEE surveillance
of all devices 4 weeks, 6 months, and 12 months following
implantation. Their observations demonstrate conclusively
that TEE surveillance is necessary for the CardioSEAL,
StarFLEX, and PFO-Star devices four weeks’ post-implant.
However, because no clots were detected by the four-week
TEE on Amplatzer devices, routine TEE surveillance in
patients with these devices should not be recommended.
Further study of the Helex and the Buttoned devices
(Custom Medical Devices, Amarillo, Texas) is necessary
before guidelines regarding a four-week surveillance TEE
can be proposed for these devices. Furthermore, Krumsdorf
et al. (19) found only three clots in 903 TEE studies
performed six months after device placement. Thus, their
recommendation for TEE at 6 and 12 months in all patients
may be excessive.
The researchers state that TTE was inadequate to detect
device-related thrombus. However, large clots (such as
those in Figure 1 of their report [19]) should be evident on
TTE if acoustic windows are adequate. Experience in
pediatric patients suggests that transthoracic surveillance of
devices may be adequate for most children and for adults
with adequate acoustic windows (7). Certainly, the risks of
TEE surveillance (sedation, aspiration, esophageal tear, and
so on) need to be considered when planning surveillance.
We suggest that TTE be performed and reviewed before
TEE. The TEE should be reserved for patients with
inadequate acoustic windows, higher-risk devices, and/or
higher-risk clinical situations.
Perhaps the report’s most important observation is that
thrombosis rates varied significantly with the devices. Al-
though no clots were found on 326 Amplatzer devices four
weeks after implantation, 5.9% of 119 CardioSEAL and
StarFLEX devices and 6.6% of 76 PFO-Star devices had
thrombus identified. These findings are consistent with our
experience at University of California-Los Angeles and with
other reports (20–22). Furthermore, although bioengi-
neered devices are under development and may prove to be
less thrombogenic than some current devices (23), in this
regard the Amplatzer devices already set an exacting stan-
dard. The problem of device-related thrombosis may not be
sufficient rationale for development of more biocompatible
devices.
The Krumsdorf et al. (19) report includes data regarding
neurological events in patients with demonstrated device-
related thrombus. Unfortunately, the data are insufficient to
draw conclusions regarding the efficacy of PFO device
closure for prevention of cryptogenic stroke. Nevertheless,
we believe that the investigators provide observations that
can help guide our current practice: Their report offers
reasonable assurance that the incidence of device thrombosis
and related embolic events appear to be low enough on all
current devices to justify continued use for ASD closure and
continued study for PFO closure. Furthermore, routine
TEE surveillance appears to be necessary after four weeks
with some devices, but not for the Amplatzer devices. After
the four-week examination, TEE surveillance should be
individualized and TTE surveillance should be employed
when acoustic windows are adequate.
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